The development and evaluation of an oncological palliative care deprescribing guideline: the ‘OncPal deprescribing guideline’

Supportive Care in Cancer

Volumn 23, Issue 1, 2015, Pages 71-78

  Lindsay, Julian ^a   Dooley, Michael ^a   Martin, Jennifer ^b   Fay, Michael ^c   Kearney, Alison ^c   Khatun, Mohsina ^d   Barras, Michael ^c  

^a MONASH UNIVERSITY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Cancer; De prescribing; Deprescribing; Drug therapy; Medical futility; Neoplasms; Potentially inappropriate medications

Indexed keywords

ACETYLSALICYLIC ACID; AGENTS ACTING ON THE EYE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIULCER AGENT; BENZODIAZEPINE DERIVATIVE; DRUG; IMMUNOMODULATING AGENT; INSULIN DERIVATIVE; LAXATIVE; OPIATE; RESPIRATORY TRACT AGENT; STEROID;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL EVALUATION; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG COST; DRUG USE; DYSLIPIDEMIA; ENDOCRINE TUMOR; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; INAPPROPRIATE PRESCRIBING; KARNOFSKY PERFORMANCE STATUS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL RECORD REVIEW; ONCPAL DEPRESCRIBING GUIDELINE; OUTCOME ASSESSMENT; POTENTIALLY INAPPROPRIATE MEDICATION; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SARCOMA; SKIN CANCER; TRANSITIONAL CELL CARCINOMA; EVALUATION STUDY; HOSPITAL PATIENT; MIDDLE AGED; NEOPLASMS; PALLIATIVE THERAPY; PROGNOSIS; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; INPATIENTS; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84919387465     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2322-0     Document Type: Article

References (16)

1. Fede A, Miranda M, Antonangelo D, Trevizan L, Schaffhausser H, Hamermesz B, Zimmermann C, Del Giglio A, Riechelmann RP (2011) Use of unnecessary medications by patients with advanced cancer: cross-sectional survey. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 19(9):1313–1318. doi:10.1007/s00520-010-0947-1
2. Jecker NS, Schneiderman LJ (1992) Futility and rationing. The American journal of medicine 92(2):189–196
3. Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M (2013) Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. doi:10.1007/s00520-013-2098-7
4. Tollier C, Fusier I, Husson MC (2005) ATC and EphMRA classifications: evolution from 1996 to 2003 and comparative analysis. Therapie 60(1):47–56
5. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine Archives of internal medicine 151(9):1825–1832
6. Hwang SS, Scott CB, Chang VT, Cogswell J, Srinivas S, Kasimis B (2004) Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress. Cancer Investig 22(5):678–687
7. Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L, Barclay S, Stone PC (2011) Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. Bmj 343:d4920. doi:10.1136/bmj.d4920
8. Tredan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, Perol D, Saba C, Quiblier F, Blay JY, Bachelot T (2011) Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 11:95. doi:10.1186/1471-2407-11-95
9. Sim J, Wright C (2005) The Kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 85(3):257–268
10. Riechelmann RP, Krzyzanowska MK, Zimmermann C (2009) Futile medication use in terminally ill cancer patients. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 17(6):745–748. doi:10.1007/s00520-008-0541-y
11. De Muth JE (2009) Overview of biostatistics used in clinical research. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists 66(1):70–81. doi:10.2146/ajhp070006
12. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA: a cancer journal for clinicians 63(1):11–30. doi:10.3322/caac.21166
13. AIHW & AACR (2012) Cancer in Australia: an overview. Cancer series Canberra: AIHW 74 (70)
14. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174
15. Australian Government Department of Health (2013) Pharmaceutical benefits scheme. Commonwealth of Australia. http://www.pbs.gov.au/pbs/home. Accessed 12/10/2013
16. Todd A, Williamson S, Husband A, Baqir W, Mahony M (2013) Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm 35(2):181–184. doi:10.1007/s11096-012-9731-2